Awakn Life Sciences Corp.

Recent News

  • Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway

    Launches Nordics Regional ExpansionDr. Lowan Stewart, One of Europe's Preeminent Ketamine Physicians, Appointed as Awakn's Regional Director for the NordicsToronto, Ontario--(Newsfile Corp. - September 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest in Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in...

    2021-09-16 7:53 AM EDT
  • Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

    Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, commented, "Our...

    2021-09-15 7:30 AM EDT
  • Awakn Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the upcoming H. C. Wainwright conference. Anthony Tennyson's, Chief Executive Officer of Awakn Life Sciences, corporate presentation will be available on-demand starting Monday, September 13th at 7:00 a.m. ET. To attend please register here.For...

    2021-09-09 7:30 AM EDT
  • Awakn Life Sciences Announces DTC Eligibility

    Toronto, Ontario--(Newsfile Corp. - September 2, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that it has received Depository Trust & Clearing Corporation ("DTC") eligibility.DTC eligibility allows Awakn's shares to be electronically cleared and settled, which will streamline the process of trading, enhance liquidity, and provide direct access to investors in the U.S. OTC capital markets. DTC is a subsidiary of the Depository...

    2021-09-02 7:30 AM EDT
  • Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

    Toronto, Ontario--(Newsfile Corp. - August 24, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicine to better treat Addiction, announced today that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.The study will be led by Celia Morgan, Ph.D., Professor of Psychopharmacology at the University of Exeter, U.K., Awakn's Head of Ketamine-Assisted Psychotherapy for Addiction and an internationally...

    2021-08-24 7:30 AM EDT
  • Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol 'AWKNF' on August 12th

    Toronto, Ontario--(Newsfile Corp. - August 12, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market ("OTCQB") under the ticker symbol "AWKNF" today, Tuesday, August 12, 2021.The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade. Trading on the OTCQB will enhance...

    2021-08-12 6:30 AM EDT
  • Awakn Life Sciences to Present at the Canaccord Genuity 41st Annual Virtual Growth Conference

    Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in Canaccord Genuity's 41st Annual Growth Conference on Tuesday, August 10, 2021. Canaccord Genuity's 41st Annual Growth ConferenceDate: Tuesday, August 10thTime: 9:30 - 9:55 a.m. ETSpeaker: Anthony TennysonWeb Link: https://wsw.com/webcast/canaccord60/awkn.ne/2940168To register for the event, ple

    2021-08-09 10:07 AM EDT
  • Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK

    The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021.Awakn Clinics London will join Awakn Clinics Bristol as the only clinics in the world providing evidence backed Ketamine-Assisted Psychotherapy for Alcohol Use Disorder.Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction,...

    2021-08-04 8:06 AM EDT